Breast Cancer :: GlaxoSmithKline announces Swiss approval of Tyverb, a new oral treatment for advanced breast cancer
GlaxoSmithKline announced an important milestone for advanced breast cancer patients across Europe with approval of the first oral ErbB1 and ErbB2 dual inhibitor, Tyverb? (lapatinib).